MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma (2022)
- Authors:
- Autor USP: REIS, FRANCISCO JOSÉ CÂNDIDO DOS - FMRP
- Unidade: FMRP
- DOI: 10.1007/s00428-021-03232-0
- Subjects: BIOMARCADORES; PROLIFERAÇÃO CELULAR; NEOPLASIAS OVARIANAS; RNA MENSAGEIRO; TAXA DE SOBREVIVÊNCIA
- Keywords: High-grade serous carcinoma; Proliferation; MCM3
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Heidelberg
- Date published: 2022
- Source:
- Título: Virchows Archiv
- ISSN: 0945-6317
- Volume/Número/Paginação/Ano: v. 480, n. 4, p. 855-871, 2022
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
KANG, Eun-Young et al. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv, v. 480, n. 4, p. 855-871, 2022Tradução . . Disponível em: https://doi.org/10.1007/s00428-021-03232-0. Acesso em: 12 fev. 2026. -
APA
Kang, E. -Y., Millstein, J., Popovic, G., Meagher, N. S., Bolithon, A., Talhouk, A., et al. (2022). MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv, 480( 4), 855-871. doi:10.1007/s00428-021-03232-0 -
NLM
Kang E-Y, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Ramus SJ, Köbel M, Reis FJC dos. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma [Internet]. Virchows Archiv. 2022 ; 480( 4): 855-871.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1007/s00428-021-03232-0 -
Vancouver
Kang E-Y, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Ramus SJ, Köbel M, Reis FJC dos. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma [Internet]. Virchows Archiv. 2022 ; 480( 4): 855-871.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1007/s00428-021-03232-0 - Diagnóstico diferencial de massas anexiais císticas : avaliação de métodos pré e pós-intervenção
- CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: an ovarian tumor tissue analysis consortium study
- Uterine serous carcinoma
- Perineal abscess three years after a transobturador sling
- Morbidity after breast cancer treatment and physiotherapeutic performance
- The influence of assessment in the learning priorities among medical students
- Relação entre o fator de crescimento endotelial vascular tumoral e o CA 125 plasmático em pacientes com neoplasias epiteliais do ovário
- Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study
- Profiling the immune landscape in mucinous ovarian carcinoma
- Impact of COVID-19 pandemic on gynecologic oncology surgery in Brasil [Editorial]
Informações sobre o DOI: 10.1007/s00428-021-03232-0 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003137595.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
